nodes	percent_of_prediction	percent_of_DWPC	metapath
Gonadorelin—Thromboembolism—Sorafenib—liver cancer	0.107	0.107	CcSEcCtD
Gonadorelin—Embolism venous—Sorafenib—liver cancer	0.0677	0.0677	CcSEcCtD
Gonadorelin—Haematoma—Sorafenib—liver cancer	0.0543	0.0543	CcSEcCtD
Gonadorelin—Embolism—Sorafenib—liver cancer	0.0532	0.0532	CcSEcCtD
Gonadorelin—Thromboembolism—Epirubicin—liver cancer	0.0397	0.0397	CcSEcCtD
Gonadorelin—Thromboembolism—Doxorubicin—liver cancer	0.0367	0.0367	CcSEcCtD
Gonadorelin—Embolism venous—Epirubicin—liver cancer	0.025	0.025	CcSEcCtD
Gonadorelin—Embolism venous—Doxorubicin—liver cancer	0.0231	0.0231	CcSEcCtD
Gonadorelin—Breast disorder—Sorafenib—liver cancer	0.0224	0.0224	CcSEcCtD
Gonadorelin—Pelvic pain—Epirubicin—liver cancer	0.0207	0.0207	CcSEcCtD
Gonadorelin—Abdominal discomfort—Sorafenib—liver cancer	0.0205	0.0205	CcSEcCtD
Gonadorelin—Embolism—Epirubicin—liver cancer	0.0197	0.0197	CcSEcCtD
Gonadorelin—Pelvic pain—Doxorubicin—liver cancer	0.0192	0.0192	CcSEcCtD
Gonadorelin—Redness—Epirubicin—liver cancer	0.0187	0.0187	CcSEcCtD
Gonadorelin—Embolism—Doxorubicin—liver cancer	0.0182	0.0182	CcSEcCtD
Gonadorelin—Redness—Doxorubicin—liver cancer	0.0173	0.0173	CcSEcCtD
Gonadorelin—Angiopathy—Sorafenib—liver cancer	0.0156	0.0156	CcSEcCtD
Gonadorelin—Immune system disorder—Sorafenib—liver cancer	0.0155	0.0155	CcSEcCtD
Gonadorelin—Erythema—Sorafenib—liver cancer	0.0149	0.0149	CcSEcCtD
Gonadorelin—Breast pain—Epirubicin—liver cancer	0.0145	0.0145	CcSEcCtD
Gonadorelin—Breast pain—Doxorubicin—liver cancer	0.0134	0.0134	CcSEcCtD
Gonadorelin—Injection site reaction—Epirubicin—liver cancer	0.0125	0.0125	CcSEcCtD
Gonadorelin—Anaphylactic shock—Sorafenib—liver cancer	0.0122	0.0122	CcSEcCtD
Gonadorelin—Shock—Sorafenib—liver cancer	0.012	0.012	CcSEcCtD
Gonadorelin—Nervous system disorder—Sorafenib—liver cancer	0.0119	0.0119	CcSEcCtD
Gonadorelin—Injection site reaction—Doxorubicin—liver cancer	0.0116	0.0116	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Sorafenib—liver cancer	0.0105	0.0105	CcSEcCtD
Gonadorelin—Fatigue—Sorafenib—liver cancer	0.0105	0.0105	CcSEcCtD
Gonadorelin—Constipation—Sorafenib—liver cancer	0.0104	0.0104	CcSEcCtD
Gonadorelin—Pain—Sorafenib—liver cancer	0.0104	0.0104	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Sorafenib—liver cancer	0.00996	0.00996	CcSEcCtD
Gonadorelin—Abdominal pain—Sorafenib—liver cancer	0.00963	0.00963	CcSEcCtD
Gonadorelin—Hypersensitivity—Sorafenib—liver cancer	0.00897	0.00897	CcSEcCtD
Gonadorelin—Asthenia—Sorafenib—liver cancer	0.00874	0.00874	CcSEcCtD
Gonadorelin—Pruritus—Sorafenib—liver cancer	0.00862	0.00862	CcSEcCtD
Gonadorelin—Diarrhoea—Sorafenib—liver cancer	0.00833	0.00833	CcSEcCtD
Gonadorelin—Breast disorder—Epirubicin—liver cancer	0.00828	0.00828	CcSEcCtD
Gonadorelin—Vomiting—Sorafenib—liver cancer	0.00774	0.00774	CcSEcCtD
Gonadorelin—Breast disorder—Doxorubicin—liver cancer	0.00766	0.00766	CcSEcCtD
Gonadorelin—Headache—Sorafenib—liver cancer	0.00763	0.00763	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Epirubicin—liver cancer	0.00736	0.00736	CcSEcCtD
Gonadorelin—Nausea—Sorafenib—liver cancer	0.00724	0.00724	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00681	0.00681	CcSEcCtD
Gonadorelin—Angiopathy—Epirubicin—liver cancer	0.00575	0.00575	CcSEcCtD
Gonadorelin—Immune system disorder—Epirubicin—liver cancer	0.00572	0.00572	CcSEcCtD
Gonadorelin—Erythema—Epirubicin—liver cancer	0.00552	0.00552	CcSEcCtD
Gonadorelin—Flatulence—Epirubicin—liver cancer	0.00544	0.00544	CcSEcCtD
Gonadorelin—Angiopathy—Doxorubicin—liver cancer	0.00532	0.00532	CcSEcCtD
Gonadorelin—Immune system disorder—Doxorubicin—liver cancer	0.0053	0.0053	CcSEcCtD
Gonadorelin—Erythema—Doxorubicin—liver cancer	0.0051	0.0051	CcSEcCtD
Gonadorelin—Flatulence—Doxorubicin—liver cancer	0.00503	0.00503	CcSEcCtD
Gonadorelin—Anaphylactic shock—Epirubicin—liver cancer	0.0045	0.0045	CcSEcCtD
Gonadorelin—Shock—Epirubicin—liver cancer	0.00443	0.00443	CcSEcCtD
Gonadorelin—Nervous system disorder—Epirubicin—liver cancer	0.00441	0.00441	CcSEcCtD
Gonadorelin—Anaphylactic shock—Doxorubicin—liver cancer	0.00417	0.00417	CcSEcCtD
Gonadorelin—Shock—Doxorubicin—liver cancer	0.0041	0.0041	CcSEcCtD
Gonadorelin—Nervous system disorder—Doxorubicin—liver cancer	0.00408	0.00408	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Epirubicin—liver cancer	0.00389	0.00389	CcSEcCtD
Gonadorelin—Fatigue—Epirubicin—liver cancer	0.00388	0.00388	CcSEcCtD
Gonadorelin—Pain—Epirubicin—liver cancer	0.00385	0.00385	CcSEcCtD
Gonadorelin—Constipation—Epirubicin—liver cancer	0.00385	0.00385	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Epirubicin—liver cancer	0.00368	0.00368	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.0036	0.0036	CcSEcCtD
Gonadorelin—Fatigue—Doxorubicin—liver cancer	0.00359	0.00359	CcSEcCtD
Gonadorelin—Pain—Doxorubicin—liver cancer	0.00356	0.00356	CcSEcCtD
Gonadorelin—Constipation—Doxorubicin—liver cancer	0.00356	0.00356	CcSEcCtD
Gonadorelin—Abdominal pain—Epirubicin—liver cancer	0.00356	0.00356	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Doxorubicin—liver cancer	0.00341	0.00341	CcSEcCtD
Gonadorelin—Hypersensitivity—Epirubicin—liver cancer	0.00332	0.00332	CcSEcCtD
Gonadorelin—Abdominal pain—Doxorubicin—liver cancer	0.00329	0.00329	CcSEcCtD
Gonadorelin—Asthenia—Epirubicin—liver cancer	0.00323	0.00323	CcSEcCtD
Gonadorelin—Pruritus—Epirubicin—liver cancer	0.00318	0.00318	CcSEcCtD
Gonadorelin—Diarrhoea—Epirubicin—liver cancer	0.00308	0.00308	CcSEcCtD
Gonadorelin—Hypersensitivity—Doxorubicin—liver cancer	0.00307	0.00307	CcSEcCtD
Gonadorelin—Asthenia—Doxorubicin—liver cancer	0.00299	0.00299	CcSEcCtD
Gonadorelin—Pruritus—Doxorubicin—liver cancer	0.00295	0.00295	CcSEcCtD
Gonadorelin—Vomiting—Epirubicin—liver cancer	0.00286	0.00286	CcSEcCtD
Gonadorelin—Diarrhoea—Doxorubicin—liver cancer	0.00285	0.00285	CcSEcCtD
Gonadorelin—Headache—Epirubicin—liver cancer	0.00282	0.00282	CcSEcCtD
Gonadorelin—Nausea—Epirubicin—liver cancer	0.00267	0.00267	CcSEcCtD
Gonadorelin—Vomiting—Doxorubicin—liver cancer	0.00265	0.00265	CcSEcCtD
Gonadorelin—Headache—Doxorubicin—liver cancer	0.00261	0.00261	CcSEcCtD
Gonadorelin—Nausea—Doxorubicin—liver cancer	0.00247	0.00247	CcSEcCtD
